Regenxbio

RegenxBio touts positive data for rare disease drug RGX-121
Clinical Trials Arena
Wed, 09/4/24 - 11:20 am
Regenxbio
RGX-121
clinical trials
Hunter Syndrome
Regenxbio CEO to step down after 15 years
BioPharma Dive
Wed, 06/12/24 - 11:23 pm
Regenxbio
Pharma CEOs
gene therapy
Kenneth Mills
AbbVie and Regenxbio’s ‘multibillion-dollar opportunity’ in vision loss gene therapy
Pharma Voice
Wed, 04/24/24 - 08:42 am
Regenxbio
AbbVie
gene therapy
ABBV-RGX-314
wet age-related macular degeneration
diabetic retinopathy
Regenxbio data suggest ‘niche’ in Duchenne gene therapy
BioPharma Dive
Thu, 03/7/24 - 11:05 am
Regenxbio
Duchenne Muscular Dystrophy
DMD
RGX-202
Sarepta Therapeutics
Elevidys
Regenxbio unveils positive data from diabetic retinopathy therapy trial
Clinical Trials Arena
Mon, 11/6/23 - 11:27 am
Regenxbio
clinical trials
ABBV-RGX-314
diabetic retinopathy
Chasing Pfizer and Roche, Regenxbio benefits from FDA boost for DMD gene therapy
Fierce Biotech
Tue, 04/11/23 - 11:32 am
Regenxbio
adeno-associated viruses
Duchenne Muscular Dystrophy
FDA
Duchenne muscular dystrophy’s progress so far in 2023
Clinical Trials Arena
Wed, 02/22/23 - 10:00 am
Duchenne Muscular Dystrophy
DMD
Santhera Pharmaceuticals
ReveraGen
vamorolone
Regenxbio
RGX-202
RegenXBio gets FDA support for Hunter syndrome gene therapy's accelerated review filing—in 2024
Fierce Biotech
Wed, 08/3/22 - 10:58 am
Regenxbio
Hunter Syndrome
RGX-121
accelerated approval
FDA
Amgen, GSK, Regenxbio and others urge SCOTUS to review 'damaging' decision on biomedical patents
Endpoints
Tue, 07/19/22 - 10:01 pm
Amgen
GSK
Regenxbio
Supreme Court
innovation
patents
Regenxbio expands MPS I gene therapy trial after first look at data
Pharmaforum
Fri, 02/11/22 - 10:28 am
Regenxbio
gene therapy
Hurler Syndrome
RGX-111
Why AbbVie Just Made a $1.8 Billion Gene Therapy Deal
Motley Fool
Sat, 09/25/21 - 11:00 pm
AbbVie
Regenxbio
gene therapy
wet age-related macular degeneration
Zolgensma patent spat brews between Novartis and Regenxbio as top Novartis gene therapy exec departs
Endpoints
Mon, 09/20/21 - 11:15 am
Regenxbio
gene therapy
patents
Novartis
Zolgensma
SMA
AbbVie, Regenxbio enter deal to develop retinal disease therapy
Reuters
Mon, 09/13/21 - 10:29 am
AbbVie
Regenxbio
RGX-314
gene therapy
retinal disease
Sarepta faces another gene therapy hiccup as Regenxbio sues over Jim Wilson's patent
Endpoints
Thu, 09/17/20 - 10:40 am
Sarepta Therapeutics
gene therapy
Regenxbio
Duchenne Muscular Dystrophy
Regenxbio sues FDA over gene therapy clinical hold
Fierce Biotech
Mon, 11/11/19 - 11:02 am
Regenxbio
FDA
clinical hold
gene therapy
clinical trials
Big Pharma Has Mad Love For These 2 Biotechs
Motley Fool
Fri, 10/11/19 - 10:41 pm
Big Pharma
biotechs
Regenxbio
Denali Therapeutics
More M&A Activity Expected Around AAV-Based Gene Therapies, Analyst Says
BioSpace
Wed, 08/7/19 - 11:34 pm
gene therapy
M&A
Audentes Therapeutics
Regenxbio
Passage Bio
RegenxBio and Pfizer Partner on Gene Therapy for Friedreich's Ataxia
BioSpace
Wed, 07/31/19 - 11:50 pm
Regenxbio
Pfizer
gene therapy
Friedreich's Ataxia
15 For ’19: Key Clinical Data To Watch For Next Year (Part 1)
Xconomy
Mon, 12/17/18 - 09:44 am
clinical trials
Alzheimer's disease
Biogen
Duchenne Muscular Dystrophy
Pfizer
Solid Biosciences
Sarepta Therapeutics
hemophilia A
Biomarin
Multiple Myeloma
Celgene
Bluebird Bio
Amgen
solid tumors
Bristol-Myers Squibb
Nektar Therapeutics
age-related macular degeneration
Regenxbio
SAGE Therapeutics
MorphoSys
RegenxBio rally fades fast after biotech reports setbacks, hospitalization in gene therapy study
Endpoints
Wed, 08/8/18 - 09:53 am
Regenxbio
gene therapy
RGX-501
clinical trials
HoFH

Pages